Abstract
Background
The Japan Renal Biopsy Registry (J-RBR), the first nation-wide registry of renal biopsies in Japan, was established in 2007, and expanded to include non-biopsy cases as the Japan Kidney Disease Registry (J-KDR) in 2009. The J-RBR/J-KDR is one of the biggest registries for kidney diseases. It has revealed the prevalence and distribution of kidney diseases in Japan. This registry system was meant to be revised after 10 years.
Methods
In 2017, the Committees of the Japanese Society of Nephrology started a project for the revision of the J-RBR/J-KDR. The revised system was designed in such a way that the diagnoses of the patients could be selected from the Diagnosis Panel, a list covering almost all known kidney diseases, and focusing on their pathogenesis rather than morphological classification. The Diagnosis Panel consists of 22 categories (18 glomerular, 1 tubulointerstitial, 1 congenital/genetical, 1 transplant related, and 1 other) and includes 123 diagnostic names. The items for clinical diagnosis and laboratory data were also renewed, with the addition of the information on immunosuppressive treatment.
Results
The revised version of J-RBR/J-KDR came into use in January 2018. The number of cases registered under the revised system was 2748 in the first year. The total number of cases has reached to 43,813 since 2007.
Conclusion
The revised version 2018 J-RBR/J-KDR system attempts to cover all kidney diseases by focusing on their pathogenesis. It will be a new platform for the standardized registration of kidney biopsy cases that provides more systemized data of higher quality.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
The Japan Renal Biopsy Registry (J-RBR), the first nation-wide web-based registry of renal biopsies in Japan, was established in 2007 [1]. The renal biopsy is the gold standard for the classification and diagnosis of kidney diseases, and it provides essential information for managing the condition [2,3]. It can also provide us with information on the incidence and distribution of kidney diseases. From the 1980s, the results of renal biopsy registry studies have been reported from all over the world [4,5,6,7].
In 2009, the Japan Kidney Disease Registry (J-KDR) which includes non-biopsy cases in addition to those registered in the J-RBR was started [8]. Thereafter, the kidney diseases that do not require renal biopsy, such as polycystic kidney disease and congenital anomalies of the kidney and urinary tract (CAKUT), could also be registered. As of December 2017, 143 nephrology centers have joined the J-RBR/J-KDR, which includes 40,369 patients in total: 37,215 biopsy cases and 3154 non-biopsy cases [9]. The cross-sectional data from the J-RBR/J-KDR have revealed the demographics of kidney diseases in Japan [10,11,12,13,14,15,16,17,18] and provided fundamental knowledge for ancillary studies [19,20,21,22,23,24].
In the original J-RBR/J-KDR 2007 system, diagnosis of the patients consists of three components: (i) a clinical diagnosis, (ii) a histological diagnosis by pathogenesis, and (iii) a histological diagnosis by histopathology (Online Resource 1) [1]. It followed the classification of glomerular diseases that was originally proposed in the 1980s by the World Health Organization (WHO) and revised in the 1990s [25,26]. This classification describes histopathological patterns of glomerular injury but does not encompass its etiology. Recently, Sethi et al. suggested a pathogenesis-based classification for glomerulonephritis [27], however, that did not include major proteinuric glomerular diseases, such as minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and tubulointerstitial diseases. Therefore, it was necessary to establish a comprehensive classification, which covers all categories of biopsy-proven kidney diseases based on their pathogenesis.
The Committee for Renal Biopsy and Disease Registry of the Japanese Society of Nephrology revised the J-RBR/J-KDR system to establish a more practical histopathological grouping and classification of the kidney diseases.
Materials and methods
Participants and data collection
The J-RBR/J-KDR collects clinical data and pathological diagnoses of patients from the collaborative institutes in Japan. These data are registered via the web page of the J-RBR/J-KDR (Fig. 1) utilizing the system of Internet Data and Information Center for Medical Research (INDICE) in the University Hospital Medical Information Network (UMIN). The essential points of this revision are described below.
Clinical diagnoses
The clinical diagnoses of the patients are selected from the list shown in Fig. 1, which includes urinary abnormalities, acute nephritic syndrome, chronic nephritic syndrome, rapidly progressive nephritic syndrome, nephrotic syndrome, acute kidney injury (AKI), chronic kidney dysfunction, and others. These clinical diagnoses are defined by current related guidelines or WHO classification [26,28,29,30,31]. The revised system of the J-RBR/J-KDR 2018 allows the registration of multiple clinical diagnoses for each case in case of overlapping clinical symptoms e.g., an MCD case demonstrated with acute kidney injury. A new category for urinary abnormalities was added to describe the patients whose biopsy was followed by asymptomatic mild hematuria and/or proteinuria.
Pathological diagnoses
-
1.
Overview of the diagnosis panel
The pathological diagnoses for registration are selected from the “Diagnosis Panel” in the web page of J-RBR/J-KDR. Clicking the button of the panel on the web page opens the list of the diagnoses as shown in Table 1. It is the main part of this revision, and constructed based on two principles. First, we tried to cover all the diagnostic names of kidney diseases including the rare ones. The panel contains 22 categories of renal diseases: 18 glomerular, 1 tubulointerstitial, 1 congenital/genetical, 1 transplant related, and 1 other, including 123 diagnostic names. In the registration process, the most appropriate diagnosis should be selected from the panel as principal diagnosis. For complex cases with multiple diagnoses, such as lupus nephritis with findings of diabetic nephropathy, additional panels for secondary diagnosis are set on the web page of the J-RBR/J-KDR.
Second, the diagnostic names of the kidney diseases will be registered based on their pathogenesis rather than morphology. For example, a patient with MN induced by hepatitis B virus (HBV) infection is registered into the category of infection-related glomerulonephritis and not MN.
Additional information, such as the name of specific drug that provoked drug-induced secondary MCD, may be entered in the <13. Description Box; Diagnosis> in the main page of the J-RBR/J-KDR registration (Fig. 1). This panel was reviewed by the Japanese Renal Pathology Society.
-
2.
Detailed pathological classification (optional)
In this revision, we added more items for detailed pathological classification of several glomerular diseases, such as the Oxford Classification [32,33,34] and Japanese Histological Grade [35] for IgA nephropathy, the Columbia Classification for FSGS [36], the International Society of Neurology and the Renal Pathology Society (ISN/RPS) classification for Lupus nephritis [37], the International Study of Kidney Disease in Children (ISKDC) classification for Henoch-Schönlein purpura nephritis [38], and the European Vasculitis Study Group (EUVAS) classification for ANCA-associated vasculitis [39].
Clinical data
-
1.
Physical measurements and laboratory data
The revised system collects baseline clinical data (Fig. 1). The baseline is defined in the next section. The clinical variables include patient characteristics and physical measurements (age, sex, height, body weight, and systolic/diastolic blood pressure), comorbidities (hypertension, diabetes, infection of HBV, hepatitis C virus, or human immunodeficiency virus), urinary findings (qualitative testing for urinary protein, occult blood, and red blood cells, and quantitative measurement of urinary protein creatinine ratio and daily proteinuria), and blood test findings (serum creatinine, total protein, albumin, total cholesterol, CRP, and HbA1c). Estimated glomerular filtration rate (eGFR) is calculated from the patient’s age, sex, and serum creatinine level using the equations for Japanese children [40] and adults [41] at the time of analysis.
-
2.
Treatment status of the “baseline”
In patients who received immunosuppressive treatment before biopsy, laboratory data at biopsy may be modified by the treatment. Information on the treatment status including whether the case is a new onset one or relapsed one will also be collected. The “baselines” for collecting clinical data are defined as follows (Fig. 1). Regarding the cases in which immunosuppressive treatment started or strengthened within 1 month prior to biopsy, the time just before the initiation of treatment is considered to be the baseline. In the cases in which immunosuppressive treatment started or strengthened more than 1 month prior to biopsy, the time of biopsy is considered as the baseline. In the cases in which immunosuppressive treatment started or strengthened within 1 month prior to biopsy but the data just before the treatment were not available, the time of biopsy is considered to be the baseline.
Results
The revised system of J-RBR/J-KDR came into use in January 2018. As of December 2018, the number of cases registered under the revised system had reached 2748 in the first year from 146 facilities. The total number of the cases registered in the J-RBR/J-KDR had reached 43,813 from the beginning of J-RBR in 2007.
Discussion
The J-RBR/J-KDR is a nationwide web-based registry in Japan, which has been conducted for more than 10 years, and it is one of the biggest registries for patients with kidney diseases including biopsy cases. We revised its registration system in 2018 with several strengths.
Clinical diagnoses that can represent the clinical status of the patients
The clinical diagnoses in the revised system enable to describe the clinical status of the patients more accurately based on the following modifications. First, the revised J-RBR/J-KDR allows the selection of all clinical diagnoses that are appropriate for the patients from the 8 listed items. Although the clinical indications for kidney biopsy vary [6], we sometimes experience patients who have multiple clinical symptoms that lead to biopsy. For example, 20–30% of the patients with MCD were reported to have demonstrated AKI [42]. If only one clinical diagnosis is registered in such cases, both the clinical diagnoses, nephrotic syndrome and AKI, could be underestimated. Second, the items indicating abnormalities in urinalysis were added. In Japan, a nationwide annual health examination program including urinalysis screening for all community residents has been going on for over 40 years [43]. It enables early detection of urine abnormalities and early referral to a nephrologist, and it is possible that a substantial number of the patients have undergone renal biopsy due to asymptomatic hematuria and/or proteinuria. Therefore, the revised J-RBR/J-KDR 2018 can describe clinical features of such patients.
Classification of kidney diseases and the structure of their registry system
For kidney diseases, the classification system should meet the following requirements: (a) clinically significant, useful, and therapeutically relevant, (b) based on pathogenesis within current knowledge, (c) easy to use and morphologically reproducible and (d) able to provide the information for prognosis [44]. Although the terminology of kidney diseases has been mainly based upon morphology, the pathogenesis of kidney diseases has been gradually revealed in recent decades. For example, membranous proliferative glomerulonephritis (MPGN) has been recognized as a pattern of glomerular injury and indicates a grouping of the patients who share common light microscopic findings. Nowadays, the cases with dysregulation of the alternative pathway of complement in MPGN are subdivided into C3 glomerulopathy [45]. Considering these advances, a classification based on etiology and pathogenesis is more desirable [44].
In addition, the value of a registry depends on its data quality, clarity of registration method, and ease of using the collected data [46]. The WHO classification [25,26], which was the fundamental concept behind the original J-RBR/J-KDR 2007 system, embodies the idea that the pathology of kidney diseases should be comprehensively interpreted with the integration of clinical, histopathological, and pathognomonic diagnoses. However, this classification was basically weighted in favor of morphology, not pathogenesis. Further, this complicating method made difficulty in data aggregation and not all diagnoses are suitable for being expressed by this method (e.g., MCD or diabetic nephropathy). In this revised system, the most appropriate diagnosis for the patients can be selected from the diagnosis panel, and this simple method will provide high reproducibility in registration.
Clinical data collection with the information of treatment status
Most of registries for kidney diseases collect the clinical data at the time of biopsy. However, it is difficult to interpret the laboratory data of patients without information on the treatment status. For example, we cannot distinguish the patients who demonstrated non-nephrotic range proteinuria from those who showed the improvement in nephrotic syndrome as a result of immunosuppressive treatment from their laboratory data alone. The revised J-RBR/J-KDR 2018 collects the information whether the laboratory data were collected before or after starting the immunosuppressive treatment. In this revision, based on these status, different “baselines” are defined for each case and it will provide more reliable data to describe the laboratory features of kidney diseases.
Problems requiring further discussion
The revised J-RBR/J-KDR 2018 system has several points that require further discussion. First, the borderline between the terms, “Primary (idiopathic)” and “Secondary,” in the glomerular disease is ambiguous. For example, primary MCD and FSGS are considered as a spectrum of diseases that are provoked by humoral permeability factors [47], while secondary cases indicate the presence of an identifiable etiology [48,49]. However, the identities of the permeability factors for MCD/FSGS are yet to be revealed [50]. For MN, the antibodies against potent etiological factors, such as the phospholipase A2 receptor (PLA2R) [51] and thrombospondin type-1 domain-containing 7A (THSD7A) [52], have been detected. Therefore, the classification based on the terminology of “primary” that indicates an unknown etiology may no longer make sense for patients with MN [53].
Second, this revision does not completely cover the recently reported disorders, such as tubulointerstitial nephritis with IgM-positive plasma cells [54]. Furthermore, in the near future, the newly developed technical approaches in kidney research including multi-omics analysis will probably reveal new pathogenesis for kidney diseases [55,56],therefore, it is necessary to continue the revision of the diagnosis panel with every new result.
Conclusion and future perspectives
The revised J-RBR/J-KDR 2018 system has attempted to cover the current classification and diagnosis of kidney diseases based on pathogenesis. It can provide data of higher quality on the demographics of kidney diseases and their classifications. In addition, the revised J-RBR/J-KDR 2018 system will be a platform for standardized registration of kidney diseases, and with this platform, we expect to promote international collaborations in research.
References
Sugiyama H, Yokoyama H, Sato H, et al. Japan Renal Biopsy Registry: the first nationwide, web-based, and prospective registry system of renal biopsies in Japan. Clin Exp Nephrol. 2011;15(4):493–503.
Cohen AH, Nast CC, Adler SG, et al. Clinical utility of kidney biopsies in the diagnosis and management of renal disease. Am J Nephrol. 1989;9:309–15.
Richards NT, Darby S, Howie AJ, et al. Knowledge of renal histology alters patient management in over 40% of cases. Nephrol Dial Transpl. 1994;23:1255–9.
Woo KT, Chan CM, Chin YM, et al. Global evolutionary trend of the prevalence of primary glomerulonephritis over the past three decades. Nephron Clin Pract. 2010;116:337–46.
McGrogan A, Franssen CFM, De Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transpl. 2011;26:414–30.
Fiorentino M, Bolignano D, Tesar V, et al. Renal biopsy in 2015—from epidemiology to evidence-based indications. Am J Nephrol. 2016;43:1–19.
O’Shaughnessy MM, Hogan SL, Thompson BD, et al. Glomerular disease frequencies by race, sex and region: results from the international kidney biopsy survey. Nephrol Dial Transpl. 2018;33:661–9.
Sugiyama H, Yokoyama H, Sato H, et al. Japan Renal Biopsy Registry and Japan Kidney Disease Registry: committee report for 2009 and 2010. Clin Exp Nephrol. 2013;17:155–73.
Sugiyama H, Shimizu A, Sato H. Annual report of J-RBR/J-KDR 2018 [in Japanese]. https://cdn.jsn.or.jp/news/180711_kp.pdf. Accessed 31 Dec 2019.
Yokoyama H, Taguchi T, Sugiyama H, et al. Membranous nephropathy in Japan: Analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2012;16:557–63.
Yokoyama H, Narita I, Sugiyama H, et al. Drug-induced kidney disease: a study of the Japan Renal Biopsy Registry from 2007 to 2015. Clin Exp Nephrol. 2016;20:720–30.
Komatsu H, Fujimoto S, Yoshikawa N, et al. Clinical manifestations of Henoch-Schönlein purpura nephritis and IgA nephropathy: comparative analysis of data from the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2016;20:552–60.
Nishi S, Muso E, Shimizu A, et al. A clinical evaluation of renal amyloidosis in the Japan renal biopsy registry: a cross-sectional study. Clin Exp Nephrol. 2017;21:624–32.
Ichikawa K, Konta T, Sato H, et al. The clinical and pathological characteristics of nephropathies in connective tissue diseases in the Japan Renal Biopsy Registry. Clin Exp Nephrol. 2017;21:1024–9.
Hiromura K, Ikeuchi H, Kayakabe K, et al. Clinical and histological features of lupus nephritis in Japan: a cross-sectional analysis of the Japan Renal Biopsy Registry (J-RBR). Nephrology (Carlton). 2017;22:885–91.
Nakagawa N, Hasebe N, Hattori M, et al. Clinical features and pathogenesis of membranoproliferative glomerulonephritis: a nationwide analysis of the Japan renal biopsy registry from 2007 to 2015. Clin Exp Nephrol. 2018;22:797–807.
Okabayashi Y, Tsuboi N, Amano H, et al. Distribution of nephrologists and regional variation in the clinical severity of IgA nephropathy at biopsy diagnosis in Japan: a cross-sectional study. BMJ Open. 2018;8(10):e024317.
Katsuno T, Ito Y, Kagami S, et al. A nationwide cross-sectional analysis of thrombotic microangiopathy in the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2020. https://doi.org/10.1007/s10157-020-01896-7.
Yonekura Y, Goto S, Sugiyama H, et al. The influences of larger physical constitutions including obesity on the amount of urine protein excretion in primary glomerulonephritis: research of the Japan Renal Biopsy Registry. Clin Exp Nephrol. 2015;19:359–70.
Yokoyama H, Sugiyama H, Narita I, et al. Outcomes of primary nephrotic syndrome in elderly Japanese: retrospective analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2015;19:496–505.
Nakashima H, Kawano M, Saeki T, et al. Estimation of the number of histological diagnosis for IgG4-related kidney disease referred to the data obtained from the Japan Renal Biopsy Registry (J-RBR) questionnaire and cases reported in the Japanese Society of Nephrology Meetings. Clin Exp Nephrol. 2017;21:97–103.
Komatsu H, Fujimoto S, Maruyama S, et al. Distinct characteristics and outcomes in elderly-onset IgA vasculitis (Henoch-Schönlein purpura) with nephritis: nationwide cohort study of data from the Japan Renal Biopsy Registry (J-RBR). PLoS ONE. 2018;13(5):e0196955.
Yamamoto R, Imai E, Maruyama S, et al. Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study. Clin Exp Nephrol. 2018;22:1266–80.
Yamamoto R, Imai E, Maruyama S, et al. Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS). Clin Exp Nephrol. 2020. https://doi.org/10.1007/s10157-020-01864-1.
Churg J, Sobin LH. Renal disease: classification and atlas of glomerular diseases. Tokyo: Igakushoin; 1982.
Churg J, Bernstein J, Glassock RJ. Renal disease: classification and atlas of glomerular diseases. 2nd ed. Tokyo: Igakushoin; 1995.
Sethi S, Haas M, Markowitz GS, et al. Mayo clinic/renal pathology society consensus report on pathologic classification, diagnosis, and reporting of GN. J Am Soc Nephrol. 2016;27:1278–87.
Arimura Y, Muso E, Fujimoto S, et al. Evidence-based clinical practice guidelines for rapidly progressive glomerulonephritis 2014. Clin Exp Nephrol. 2016;20:322–41.
Nishi S, Ubara Y, Utsunomiya Y, et al. Evidence-based clinical practice guidelines for nephrotic syndrome 2014. Clin Exp Nephrol. 2016;20:342–70.
Kellum JA, Lameire N, Aspelin P, et al. Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138.
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1–S266.
Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76:534–45.
Roberts ISD, Cook HT, Troyanov S, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76:546–56.
Trimarchi H, Barratt J, Cattran DC, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017;91:1014–21.
Kawamura T, Joh K, Okonogi H, et al. A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end-stage renal disease. J Nephrol. 2013;26:350–7.
D’Agati VD, Fogo AB, Bruijn JA, et al. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis. 2004;43:368–82.
Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241–50.
Appel GB, et al. Shonlein-henoch purpura. In: Brenner BM, editor. Brenner and Rector’s the kidney. 7th ed. Philadelphia: Saunders; 2004. p. 1411–1415.
Berden AE, Ferrario F, Hagen EC, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21:1628–36.
Uemura O, Nagai T, Ishikura K, et al. Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease. Clin Exp Nephrol. 2014;18:626–33.
Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR From serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
Meyrier A, Niaudet P. Acute kidney injury complicating nephrotic syndrome of minimal change disease. Kidney Int. 2018;94:861–9.
Imai E, Yamagata K, Iseki K, et al. Kidney disease screening program in japan: history, outcome, and perspectives. Clin J Am Soc Nephrol. 2007;2:1360–6.
Zhou XJ, Laszik Z, Nadasdy T, et al. Algorithmic approach to the interpretation of renal biopsy. Silva's diagnostic renal pathology. Cambridge: Cambridge University Press; 2017. p. 69–91.
Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis—a new look at an old entity. N Engl J Med. 2012;366:1119–31.
Arts DGT, De Keizer NF, Scheffer GJ. Defining and improving data quality in medical registries: a literature review, case study, and generic framework. J Am Med Inf Assoc. 2002;9:600–11.
Maas RJ, Deegens JK, Wetzels JF. Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future. Nephrol Dial Transpl. 2014;29:2207–16.
Glassock RJ. Secondary minimal change disease. Nephrol Dial Transpl. 2003;18(Suppl 6):vi52–i58.
D’Agati VD. The many masks of focal segmental glomerulosclerosis. Kidney Int. 1994;46:1223–411.
Rovin BH, Caster DJ, Cattran DC, et al. Management and treatment of glomerular diseases (part 2): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2019;95:281–95.
Beck LH Jr, Bonegio RGB, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11–21.
Tomas NM, Beck LH Jr, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371:2277–87.
Floege J, Barbour SJ, Cattran DC, et al. Management and treatment of glomerular diseases (part 1): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2019;95:268–80.
Takahashi N, Saeki T, Komatsuda A, et al. Tubulointerstitial nephritis with IgM-positive plasma cells. J Am Soc Nephrol. 2017;28:3688–98.
Mariani LH, Kretzler M. Pro: “The usefulness of biomarkers in glomerular diseases”. The problem: Moving from syndrome to mechanism—Individual patient variability in disease presentation, course and response to therapy. Nephrol Dial Transpl. 2015;30:892–8.
Mariani LH, Pendergraft WF, Kretzler M. Defining glomerular disease in mechanistic terms: implementing an integrative biology approach in nephrology. Clin J Am Soc Nephrol. 2016;11:2054–60.
Acknowledgements
The authors are grateful to all their colleagues who participated in the J-RBR (Online Resource 2). This study was supported in part by a Grant-in-Aid for Intractable Renal Diseases Research, Research on Rare and Intractable Diseases, and Health and Labor Sciences Research Grants from the Ministry of Health, Labor, and Welfare of Japan (H29-nanchi-ippan-017).
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
All the authors have declared no competing interests.
Ethics approval
The J-RBR/J-KDR and its revision were approved from the ethical committee of the Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences (approval number: 233) and the Japanese Society of Nephrology [approval number: 62(3-6)]. All the participating institutions and hospitals individually approved this study. All procedures performed in this study involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. J-RBR/J-KDR is registered with the UMIN Clinical Trial Registry (UMIN000000618).
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Ozeki, T., Maruyama, S., Nagata, M. et al. The revised version 2018 of the nationwide web-based registry system for kidney diseases in Japan: Japan Renal Biopsy Registry and Japan Kidney Disease Registry. Clin Exp Nephrol 24, 1058–1068 (2020). https://doi.org/10.1007/s10157-020-01932-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10157-020-01932-6